Organization | Chinese SLE Treatment And Research Group

Chinese SLE Treatment And Research Group Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial

2015

NCT02444728

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Chinese SLE Treatment and Registration Group | Chinese SLE Treatment And Research Group

Active Ingredients

Drugs in Phase 4 Trials (3)

adalimumab (humira) (1 trial)

kunxian (1 trial)

naltrexone (revia) (2 trials)

Drugs in Phase 3 Trials (6)

azathioprine (imuran) (2 trials)

cyclophosphamide (cytoxan) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

methylprednisolone (medrol) (1 trial)

mycophenolate (myfortic) (1 trial)

Drugs in Phase 2 Trials (1)

sirolimus (rapamune) (1 trial)

Drugs in Other Trials (1)

leflunomide (arava) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Aortic Arch Syndromes (Phase 3)

Arteritis (Phase 3)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Lupus Erythematosus, Systemic (Phase 2)

Takayasu Arteritis (Phase 3)

Thrombocytopenia (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 11